iBio: Funding, Investors & Team (Oct 2026)
iBio utilizes its iBioLaunch™ and iBioModulator™ platforms to develop and offer product applications to partners, providing comprehensive support for the implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a unique technology for producing biologics using transient gene expression in unaltered green plants. This method offers advantages such as the ability to produce proteins that are challenging or impossible to create with other techniques, applicable to a wide range of biologics, and allows for quick development and validation of flexible and scalable manufacturing facilities. Other benefits include increased capacity for responding to bioterrorism or pandemics, freedom from traditional process patents, and lower production costs compared to other methods.
iBio has raised $91.0M across 3 funding rounds on record, the most recent an undisclosed round of $26.0M announced in Jan 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
iBio Company Profile and Key Stats
Latest funding round on record: Jan 2026.
iBio Funding Rounds
iBio raised $15.0M in an undisclosed round announced in Mar 2024.
1.4 years later, an undisclosed round of $50.0M was announced in Aug 2025.
5 months later, an undisclosed round of $26.0M was announced in Jan 2026.
iBio Founders and Leadership Team
No contact details are on record for this team yet.
iBio Funding Compared to Other Biotechnology Startups
iBio's latest round of $26.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like iBio in Biotechnology and Newark
Companies Similar to iBio
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
iBio Funding FAQs
What does iBio do?
iBio utilizes its iBioLaunch™ and iBioModulator™ platforms to develop and offer product applications to partners, providing comprehensive support for the implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a unique technology for producing biologics using transient gene expression in unaltered green plants. This method offers advantages such as the ability to produce proteins that are challenging or impossible to create with other techniques, applicable to a wide range of biologics, and allows for quick development and validation of flexible and scalable manufacturing facilities. Other benefits include increased capacity for responding to bioterrorism or pandemics, freedom from traditional process patents, and lower production costs compared to other methods.
How much funding has iBio raised?
iBio has raised $91.0M across 3 rounds on record. The most recent is an undisclosed round of $26.0M announced in Jan 2026.
When did iBio last raise funding?
iBio's most recent funding round on record is an undisclosed round of $26.0M, announced in Jan 2026.
Who founded iBio?
FundedIQ lists Robert B Kay (Founder) at iBio.
Where is iBio headquartered?
iBio is based in Newark, Delaware, United States.
How many employees does iBio have?
iBio is in the 51-100 employee band.
How does iBio's funding compare to other Biotechnology startups?
iBio's latest round of $26.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's iBio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for iBio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.